Weighing the hazards of erythropoiesis stimulation in patients with cancer.
Khuri
Fadlo R
FR
Emory Winship Cancer Institute, Atlanta, USA.
D026683:Advisory Committees; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D000068256:Darbepoetin alfa; D004348:Drug Labeling / Q000331:legislation & jurisprudence; D004335:Drug and Narcotic Control; D000068817:Epoetin Alfa; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000009:adverse effects* / Q000031:analogs & derivatives*; D006397:Hematinics / Q000009:adverse effects*; D006801:Humans; D009369:Neoplasms / Q000150:complications / Q000401:mortality* / Q000473:pathology; D011994:Recombinant Proteins; D012306:Risk; D013268:Stimulation, Chemical; D013923:Thromboembolism / Q000139:chemically induced; D014481:United States; D014486:United States Food and Drug Administration
D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa